Lentivirus can be engineered to be a highly potent vector for gene therapy applications. However, generation of clinical grade vectors in enough quantities for therapeutic use is still troublesome and limits the preclinical and clinical experiments. As a first step to solve this unmet need we recently introduced a baculovirus-based production system for lentiviral vector (LV) production using adherent cells. Herein, we have adapted and optimized the production of these vectors to a suspension cell culture system using recombinant baculoviruses delivering all elements required for a safe latest generation LV preparation. High-titer LV stocks were achieved in 293T cells grown in suspension. Produced viruses were accurately characterized and the functionality was also tested in vivo. Produced viruses were compared with viruses produced by calcium phosphate transfection method in adherent cells and polyethylenimine transfection method in suspension cells. Furthermore, a scalable and cost-effective capture purification step was developed based on a diethylaminoethyl monolithic column capable of removing most of the baculoviruses from the LV pool with 65% recovery.
INTRODUCTION
Lentiviruses have shown their capabilities in gene therapy as they transduce both dividing and non-dividing cells and allow long-term transgene expression. 1 However, their production has proved to be challenging, partly because of the toxicity related to some viral proteins and the vesicular stomatitis virus glycoprotein G (VSV-G) envelope protein. 2 This has complicated the development of stable production cell lines. 3 Another concern is the safety of HIV-based vectors. In this regard, the development of lentiviral vectors (LVs) has led to the splitting of the viral genome into three or four plasmids which are used in the transient transfection method to generate LVs. [4] [5] [6] [7] The most commonly used reagent in transfection is calcium phosphate. 6, 8, 9 Recently polyethylenimine (PEI)-mediated transfection in serum-free conditions has also gained interest. 10 The scaling up of an adherent cell virus production is challenging. A large-scale production typically requires the use of cell factories 11, 12 with a limited production volume and requires labor-consuming handling and difficult monitoring of culture conditions. The most practical method for a large-scale production is the use of suspension cells which allows the use of bioreactors in viral vector production. 13 Bioreactors are scalable, cost-effective and permit a tight control of culture conditions (for example, pO 2 , pCO 2 and pH). The first successful transient LV production process in suspension cells was published by Segura et al. 14 They were able to produce high-titer LVs in a 3-l bioreactor with 293-based cells grown in serum-free medium.
The transient transfection was performed with PEI. However, the polyplex formed by plasmids and PEI is toxic to the producer cells 15 and an efficient production requires thorough optimization and high quantities of plasmids.
Earlier studies have proved recombinant baculoviruses (BVs) to be versatile tools for many kinds of biotechnological applications, such as gene delivery and the production of proteins and vaccines. [16] [17] [18] The latest applications include the production of viral vectors, especially adeno-associated virus, for gene therapy. 13, 19, 20 We developed recently a production method for LVs by transduction of adherent cells with BVs. 21 The aim of the current study was to further improve this novel LV production system and adapt it into suspension cells ( Figure 1 ) to solve the yet unsolved issue of large-scale LV production for preclinical and clinical trials.
The purification of LVs is challenging because of the fragile nature of the enveloped virion. This is why LVs are still routinely used after simple concentration by ultracentrifugation without any further purification steps. 2, 6 Several purification methods, such as anionexchange chromatography, 22, 23 affinity chromatography, 14 ultrafiltration 24, 25 or sucrose gradient sedimentation 26 have been studied for LVs. Typically, retroviral vectors are purified by ultrafiltration and chromatographic steps. 27 A simple and cost-effective capture purification step for LVs is still, however, lacking. Furthermore, even though BVs do not present major safety concerns, 16 the final lentiviral product must be purified from contaminating BVs and be pure enough to be tested in clinical studies. To solve the purity demands, we show here that a diethylaminoethyl (DEAE) monolithic column operated in a bind-elute mode using linear salt elution gradient is capable of separating in a single step over 99% of the BVs from the produced high-titer LV preparations with a good recovery yield of 65%.
RESULTS
Selection of the best medium for a suspension cell transduction 293T cells can be grown in suspension using different media but the choice of a medium has an influence on cell growth, transduction efficiency and LV yield. Thus, the culture conditions were first optimized for BV transduction in 293T suspension cells. The cells were maintained in suspension using EX-CELL 293 medium (SAFC Biosciences Inc., Lenexa, KS, USA). However, transduction was performed in seven different media (EX-CELL 293, PFHM II, Opti-MEM, Iscove's Modified Dulbecco's Media (Sigma-Aldrich, St Louis, MO, USA), RPMI 1640 (Cambrex Bio Science, Verviers, Belgium), Hyclone and Freestyle 293 Expression Medium). The cells were transduced with a Green Fluorescent Protein (GFP)-expressing BV using a multiplicity of infection (MOI) of 100. Culture medium was exchanged with fresh EX-CELL 293 at 16 h post-transduction (p.t.) and GFP-positive cells (transduction efficiency) were counted by flow cytometry at 48 h p.t. The results showed that the Freestyle 293 Expression medium gave the highest (89% GFP-positive cells) transduction efficiency and was thus chosen as the production medium (Figure 2 ). High transduction efficiency was also achieved when using Hyclone and RPMI 1640 mediums whereas in the EX-CELL 293 medium only 6.7% of cells were GFP-positive.
Optimization of the LV production in small scale The production of LVs was first optimized to small-scale suspension culture using 6-well plates. The studies were performed using the BV constructs described earlier. 21 The optimal LV harvesting time was evaluated by transducing cells with the four BVs, each at MOI 100. Culture medium was exchanged with fresh medium at 16 h p.t. and the supernatant containing LVs was collected at different points over time. The supernatant was used for the transduction of HeLa cells to define the functional titer of the LV lot (Transduction Units (TU) per ml) by flow cytometry. The highest LV titers (1.2Â10 5 TU per ml) were achieved when the medium was harvested at 48 h p.t. (Figure 3a ) although the cells were still generating some virus at 144 h p.t.
The cell density was then optimized at the time of transduction. Different cell densities (1 to 10Â10 6 cells per ml) were studied. The best LV titers were achieved when the cell density was set to 3 to 4Â10 6 cells per ml (Figure 3b ). Sodium butyrate, a potent histone deacetylase inhibitor improves BV transduction efficiency by exposing the expression cassette for transcription. 28 However, sodium butyrate seems to confer a negative effect, in a dose-dependent manner, on LV production in 6-well plates (Figure 3c) .
It has been shown that physiological temperature affects BV transduction, whereas lower temperatures (26-28 1C) improve it. 29 The transduction at 26, 30, 34 and 37 1C for 3 h during LV production was therefore studied. Supernatant harvest was performed at 48 h p.t. and the LV titers were assessed. The highest titers were achieved when the transduction was performed at 30 1C but the differences in the results between the temperatures were rather small (Figure 3d ). Further studies were thus carried out at 37 1C for convenience.
For a cost-effective LV production, the dose of BVs was studied from MOI 2.5 to MOI 750 upon cell transduction. The best results were achieved at MOI 50. No further improvement on LV yields was attained by employing higher MOIs. The use of MOIs o50 yielded a dose-dependent decrease in LV titers (Figure 3e ). Different ratios of the four specific BVs used in the transduction were tested. When plasmids are used for the LV production, the transfer-plasmid is typically used more than twice the amount of the other plasmids. 6 The best LV titers were achieved when all other BVs were applied at MOI 50, except the BAC-transfer (BV containing transgene cassette) applied at MOI 250 (Figure 3f ). Statistical analysis was performed. Although the trends in the 6-well plate optimization results were evident, they were statistically insignificant because the experiments were performed in duplicates (n¼2) due to the vast amount of the samples involved.
LV production in suspension cells using roller bottles A scalable production system utilizing suspension cells was set up and optimized for roller bottles. A total of 17 batches of LVs were produced in roller bottles and produced viruses were concentrated by ultracentrifugation. The functional (infective) titer (IP) was measured by fluorescence activated cell sorting (FACS) from the harvested supernatant and after the concentration. The LVs titers were on average of 5.0Â10 5 TU per ml prior concentration and 2.0Â10 8 TU per ml after the concentration when the production conditions were based on the 6-well plate experiments. Interestingly, and contrary to what was observed on 6-well plates, the addition of 5 mM sodium butyrate boosted LV production in roller bottles yielding 2.6Â10 5 TU per ml and 5.1Â10 8 TU per ml titers, respectively ( Figure 4 ). The BV MOI used was further optimized for roller bottle transduction and the best titers (2.2Â10 6 TU per ml and 1.1Â10 9 TU per ml) were achieved when all BVs were used at MOI 25, except the BAC-transfer at MOI 125. In addition to FACS titer, the number of integrated viral genome copies on the transduced host cells was measured for last batches by real-time quantitative PCR. The functional titers based on integrated genome copy number were on average of 3.0Â10 9 TU per ml (Figures 5a and b). The total viral particle (VP) titer was estimated by p24 protein-based enzyme-linked immunosorbent assay showing that the total viral particle titers were over 2 logs higher than the functional titers ( Figure 5c ). The cell viability was measured after the transduction of suspension cells and was 92%, suggesting that VSV-G caused no major toxicity for producer cells. 2, 30 To compare the BV-produced LVs to those produced by plasmid transfection methods, GFP-expressing LVs were produced in suspension cells using the PEI method and in adherent cells using traditional calcium phosphate method. By PEI method, the functional titers were about 1 log lower compared with the BV production system whereas the particle titer was comparable (Figures 5a and c) . The quality of the PEI-generated LVs was thus substantially lower than the viruses generated using the BV strategy (Figure 5d ). The traditional calcium phosphate plasmid transfection method gave the best LV titers measured by FACS (average 5.8Â10 9 TU per ml) but, interestingly, the viral titering based on integrated genome copy number showed no difference to the BV-generated LVs. Figure 5d shows that the best quality LV lots were obtained using the traditional and the BV-based protocols indicating lower VP/IP ratios when compared with the PEI method, where larger quantities of non-functional viral particles were obtained. Based on the different titering methods, the quantity of LVs produced by either BVs or calcium phosphate-mediated plasmid Figure 3 Optimization of LV production in a 6-well plate scale. The effect of: harvesting time (a), cell density (b), concentration of sodium butyrate (c) and temperature during the transduction (d), were studied using BV at MOI 100. Different amounts (MOIs) (e), and ratios (f), of BVs were also tested for LV production. The optimization was performed at least in duplicates. Figure 4 Optimization of LV production in roller bottle scale. The effect of sodium butyrate and optimized BV ratio on LV titers was evaluated. The best LV titer was achieved when 5 mM sodium butyrate was used and all the BVs were used at MOI 25 except BAC-transfer, which was used at MOI 125. The data were analyzed by one-way analysis of variance (Kruskal-Wallis test) and Dunn's Multiple Comparison test (*Po0.05).
transfection was thus comparable. Suspension-based titering methods showed that the BV-transduced cells gave a specific LV productivity of 10 TU per cell whereas only 1 TU per cell was achieved with the PEI method. As adherent cells were seeded 1 day before the transfection and the cell calculation would have required trypsinization of the cells from the plate, the specific LV productivity was not determined for the conventional method to produce LVs. In the literature, the productivity per cell in adherent cells after calcium phosphate method has been typically between 1 and 30 but up to 65 viruses per cell has been reported. However, the titering methods differ between each other and the production scale was from 6-well plates to cell factories. 31 In vivo testing of BV-generated LVs To extend the in vitro results which showed equal quality of the BV-LV in cell transduction than the conventional LV preparations, we injected into brain of three rats by GFP-expressing lentivirus. LVs for in vivo studies were produced in roller bottles, purified by membrane chromatography and concentrated by ultracentrifugation. 7 Rat brain tissue (corpus callosum) was transduced with purified GFP-expressing LVs (totally 8Â10 5 TU) and GFP expression was observed from cryosections. GFP expression was evident in the transduction area ( Figure 6a ) compared with the control region (Figure 6b) , suggesting that the new production method did not affect the functionality of the LV in vivo.
Purification assays
To devise an efficient purification method capable of removing major contaminants, including BVs, from the LV supernatants two different capture matrices were evaluated: a Sartobind D MA75 (containing DEAE ligands; Sartorius Stedim Biotech, Göttingen, Germany) and a CIM DEAE monolithic column (BIA Separations, Ljubljana, Slovenia). Both matrices have shown to be especially suitable for large particle bioseparation as the utilization of the matrix area is maximized and mass transport limitations are greatly reduced. [32] [33] [34] [35] As shown in Table 1 , both viruses adsorbed to the matrices; however, the monolithic column presented an overall higher recovery yield. The LVs were more disperse over the course of the elution gradient step than the BVs for both matrices (Figure 7a ). However, as also shown in the highlighted fraction pool in Figure 7a , two co-eluting sharp peaks were obtained. To check whether the two peaks could be separated, we further extended the linear salt gradient used and obtained the chromatogram presented in Figure 7b . With this extended linear gradient run, 499% of the BVs were eluted in the second peak (at higher salt concentration) whereas about 65% of the LVs were obtained in the first peak. These encouraging results show that a bind-elute step based on a DEAE monolithic column (showing a higher recovery yield) is a promising purification step not only for recovery of LVs from the contaminating BVs but also for LVs produced from plasmid-transfected LV production. Total protein and host cell dsDNA contents were also assessed (Table 1) . Over 99% of both host cell/medium protein and 95% dsDNA were removed with this step.
DISCUSSION
LVs have been commonly produced by transfecting adherent cells with several plasmids. 6, 8, 36, 37 The transient transfection method is easy to perform, versatile and it avoids the time-consuming development of stable cells lines. It also allows easy and rapid testing of various transgenes or pseudotypes. 23 BVs offer a feasible alternative to plasmids as their transgene capacity is practically unlimited (4100 kb), production in high quantities and titers is fast and costeffective in antibiotic-free and serum-free conditions. Working is easy and does not require special skills. In addition, BVs do not replicate in mammalian cells, which is an important safety aspect. 16 Indeed, the BV system has been approved by the FDA (Food and Drug Administration) and European Medicines Agency for the production of vaccines, for example, the recent GlaxoSmithKline (GSK) vaccine Cervarix (GlaxoSmithKline Biologicals, Rixensart, Belgium) against cancer caused by human papillomavirus. 38 
Figure 7
Chromatographic elution on CIM DEAE monolithic column: (a) elution was carried out using two linear salt gradients: first, for 25 column volumes up to 0.4 M NaCl and next, for 5 column volumes up to 1.5 M NaCl; (b) represents a run with elution gradients of 20+20 column volumes. Bars represent pool fractions analyzed for LV titers expressed in TU per ml and BV titers expressed in TP per ml. Note that the highlighted fraction pool in (a) corresponds to the separated two pools at over 315 ml retention volume in (b). Optimized gradient e Fraction P (see Figure 7b ) 65 a 0. We have recently showed that the production of LVs is feasible in adherent cells using BVs. 21 In this work, we show for the first time that BVs can be used for the scalable production of LVs in suspension cells. This constitutes a step forward towards large-scale LV production for clinical trials, currently a critical issue. Only PEI-based plasmid transfection method has proved some promise in scalable LV generation. 14, 39 The high-quality LV production in a suspension cell culture obtained here also further supports BV potential in straightforward recombinant protein and virus particle production in vertebrate cells. 20, 40 In the current study, the production was first optimized for a small, laboratory-scale, suspension cell culture in 6-well plates to evaluate critical factors before scale-up testing. However, the result did not fully translate into the production in the roller bottles. To achieve best productivity, the culture conditions were further optimized. For example, the addition of sodium butyrate did not improve the productivity in 6-well plates, but it proved to be important in the roller bottle system. This is in line with the results by Ansorge et al., 39 showing that sodium butyrate had a significant positive impact on the production of LVs produced in perfusion bioreactors. Altogether, these results highlight the influence of the production conditions on the specific viral productivity. In agreement with earlier studies, the culture medium needs to be carefully selected. 41 The fact that LVs were produced up to 144 h p.t. potentially allows to collect viruses several times over culture time further increasing overall yields. Typically, shaker flasks have been used for optimizing culture conditions of suspension cells before large-scale vector production in bioreactors. 14 However, in this study the final goal is to scale the production into wave bioreactors where their agitation is more compared with roller bottles. LVs were characterized by several titering methods and tested for functionality in vivo. The results showed that the BV-based method compared very favorably against the other methods providing a convenient means to generate high-quality LVs.
LVs are typically concentrated in research laboratories only by ultracentrifugation without further purification. However, ultracentrifugation step also concentrates some of the host cell-derived contaminants into the final product. The contaminants and the presence of the most commonly used envelope protein, VSV-G increases the likelihood of lentivirus-mediated toxicity and the triggering of an immune response. 26, 42 Although BVs are safe to use, they do not replicate in mammalian cells and are not cytotoxic, 16 their presence in the LV preparations is a concern. Both LVs and BVs are enveloped viruses, thus per se prone to degradation through processing. 43 Furthermore, both show overall surface negative charges at physiological pH. 44, 45 As such, our rationale was to use an anionexchange bind-elute step with enough resolution to separate the two viruses upon elution. Indeed, the difference in the overall electrostatic charges of the two viruses could be turned to an advantage in a purification method using a DEAE monolithic anion-exchange column. Most of the impurities could be withdrawn in a single step with a good LV recovery (65%). Removal of host cell dsDNA was 95%. To further reduce dsDNA, an intermediate DNA digestion step, for example, using Benzonase (Merck KGaA, Darmstadt, Germany), can be implemented.
As a conclusion, BV-based generation of LVs in suspension culture provides a convenient strategy for scalable and good-quality LV production. Furthermore, the introduced purification step, based on a DEAE monolithic column, efficiently removes BVs and other major contaminants in a single, scalable step yielding highly purified LVs that can be used in gene therapy trials. 
MATERIALS AND METHODS

Cells culturing
Baculoviruses
BVs were generated as described previously; 21 BAC-transfer (expressing GFP as a transgene), BAC-gag-pol (expressing Gag and Pol genes), BAC-rev (expressing Rev) and BAC-VSV-G (expressing VSV-G for pseudotyping). The viruses were produced, characterized and titrated as described. 46 Optimization of BV-mediated LV production in 6-well plates 293T cells were cultured using EX-CELL 293 medium. Cells were seeded to the several different transduction media (density 1 to 10Â10 6 cells per ml) and transduced 4 h later with the four hybrid BVs (MOI 2.5-750, equal or different ratios). The transduction was performed at 37 1C. In addition, transductions were also performed at 26, 30 and 34 1C temperature for 3 h after which the cells were placed back to 37 1C. Cells were removed 16 h after the transduction by centrifugation (800 r.p.m., 5 min) and fresh EX-CELL 293 was added. LV containing supernatant was collected at 48-144 h p.t. Sodium butyrate concentration was 0-10 mM during the vector production.
BV-mediated LV production in suspension cells using roller bottles 293T suspension cells were cultured using EX-CELL 293 medium. At the transduction day, the cells were seeded in Freestyle 293 Expression medium (1% fetal bovine serum) and transduced 4 h later with the four BVs (different MOIs were tested). At the time of transduction the volume for a 490-cm 2 roller bottle was 30 ml and for a 850-cm 2 roller bottle was 60 ml. The medium was removed 16 h p.t. by centrifugation (800 r.p.m., 5 min) and fresh EX-CELL 293 medium was added to the cells (60 or 120 ml depending of the roller bottle size). Sodium butyrate concentration was either 0 or 5 mM during the vector production. Rotation rate was 2 r.p.m. and the temperature was kept at 37 1C during the whole production. LV containing supernatant was collected at 48 h p.t. and concentrated by ultracentrifugation. 47 First experiments were made using 490 cm 2 roller bottles and later 850 cm 2 bottle size was used. Viruses were concentrated 1000-fold by ultracentrifugation as described by Kaikkonen et al. 47 LV production in adherent and suspension cells by plasmid transfection GFP-expressing LVs were prepared in triple flasks (Nunc, Roskilde, Denmark) by a calcium phosphate transfection of adherent 293T cells as described previously. 6 Suspension cells were cultured in conditions described in previous paragraph. At the transfection day, the cells were seeded (density 1.6 to 2Â10 6 cells per ml) into Freestyle 293 Expression Medium (5 mM sodium butyrate, 1% fetal bovine serum) and transfected 2 h later with the same four plasmids that were used in adherent cells. Linear 25 kDa PEI (Polysciences Inc., Warrington, PA, USA) was used as transfection reagent. PEI was diluted into sterile water, neutralized with HCl and pH was adjusted to 7 with NaOH. PEI concentration in the preparation was 1 mg ml À1 ; the DNA to PEI mass ratio was 1:4. A plasmid ratio of 1:1:1:2 was used where the transfer construct was the one used in larger quantity. Transfection was performed as described before. 14 Culture medium was exchanged to fresh medium 16 h after the transfection and viruses were collected at 70 h. Viruses were concentrated 1000-fold by ultracentrifugation as described by Kaikkonen et al. 47 
LV titering after roller bottle production
The functional viral titer (TU per ml) was determined by transducing HeLa cells on 6-well plate and analyzing green fluorescence by FACS. 47 The amount of p24 lentiviral capsid protein (pg ml 1 À1 ) was determined by ELISA kit (PerkinElmer, Waltham, MA, USA). The quantity of the vector DNA in transduced HeLa cells was determined with an UltraRapid lentiviral titer kit (System Biosciences, Mountain View, CA, USA).
Gene delivery into rat brain
The functionality of the produced LVs in vivo was evaluated in a rat model (n¼3). LVs were produced in roller bottles as described earlier, purified by anion-exchange membrane chromatography 7 and finally concentrated by ultracentrifugation. GFP-expressing LVs (15 ml, 8Â10 5 TUs) were injected as described by Kaikkonen et al, 47 into the right corpus callosum (coordinates: 1.0 mm caudal to bregma, 2 mm right to sutura sagittalis and depth of 2.0 mm). Rats were killed 6 days after transduction and the brains were perfused with heparinized saline (0.5 ml heparin, 500 IU per 1 l saline), fixed with 4% paraformaldehyde in 0.1 M phosphate buffer (77.4 ml NaHPO 4 and 22.6 ml NaH 2 PO 4 in 1 l, pH 7.4) for 16 h, incubated for 2 days in 30% sucrose in 0.1 M phosphate buffer and finally stored at À20 1C. GFP expression in cryosections was studied by fluorescence microscopy after mounting the samples in Prolong Gold Antifade reagent (Invitrogen). All the animal experiments were approved by ethical committee in ELLA under license ESLH-2007-09482-Ym/23.
Chromatography
Sartobind D MA75 (Sartorius Stedim Biotech) membrane adsorbers with 75 cm 2 effective membrane area equivalent to B2 ml membrane volume containing DEAE functional groups were assessed against a CIM DEAE-8f tube monolithic column (BIA Separations). Both matrices were coupled to an Ä KTAexplorer100 chromatography system coupled to the UNICORN software (all GE Healthcare, Uppsala, Sweden), equipped with online UV absorbance cell detector, conductivity meter, pH sensor and a fraction collector. Both matrices were equilibrated with 10 mM Tris buffer (pH 8), before sample loading with 150 ml of LV supernatant. Flow rates varied from 5 ml min À1 (membrane) to 10 ml min À1 (monolith). After sample loading, the matrices were washed with 10 mM Tris buffer (pH 8) to remove unbound/impurity materials. Elution of the viral peaks was carried out using linear salt gradients up to 10 mM Tris buffer (pH 8) supplemented with 1.5 M NaCl. The chromatographic runs were performed inside a cold chamber, maintained between 6 and 10 1C.
Analytical assays after LV purification
The number of total BVs was monitored by real-time quantitative PCR as described by Vicente et al. 32 LV titer (TU per ml) was assessed via infection of 293 cells as described by Rodrigues et al. 48 Total protein content of samples was determined using the BCA protein assay kit (96-well plate protocol) from Pierce (Rockford, IL, USA) following the manufacturer's protocol. The quantification of total DNA content throughout processing was performed using the PicoGreen dsDNA Assay kit (Invitrogen, Paisley, UK) using 96-well plates according to the manufacturer's instructions.
Statistical analyses
Statistical analyses were performed by GraphPadPrism 5 (GraphPad Software Inc., San Diego, CA, USA). The studies were performed at least in triplicates, except the 6-well plate optimization studies, which were performed at least in duplicates. Statistical analysis of the 6-well plate experiments was carried out from the parallels used in titering. The data were analyzed by one-way analysis of variance using Kruskal-Wallis test and Dunn's Multiple post hoc test.
